205 related articles for article (PubMed ID: 26456622)
1. Genetic markers in CYP2C19 and CYP2B6 for prediction of cyclophosphamide's 4-hydroxylation, efficacy and side effects in Chinese patients with systemic lupus erythematosus.
Shu W; Guan S; Yang X; Liang L; Li J; Chen Z; Zhang Y; Chen L; Wang X; Huang M
Br J Clin Pharmacol; 2016 Feb; 81(2):327-40. PubMed ID: 26456622
[TBL] [Abstract][Full Text] [Related]
2. Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients.
Nakajima M; Komagata S; Fujiki Y; Kanada Y; Ebi H; Itoh K; Mukai H; Yokoi T; Minami H
Pharmacogenet Genomics; 2007 Jun; 17(6):431-45. PubMed ID: 17502835
[TBL] [Abstract][Full Text] [Related]
3. Cytochrome P450 polymorphisms and the response of lupus nephritis to cyclophosphamide therapy.
Winoto J; Song H; Hines C; Nagaraja H; Rovin BH
Clin Nephrol; 2011 May; 75(5):451-7. PubMed ID: 21543025
[TBL] [Abstract][Full Text] [Related]
4. The importance of both CYP2C19 and CYP2B6 germline variations in cyclophosphamide pharmacokinetics and clinical outcomes.
Helsby NA; Yong M; van Kan M; de Zoysa JR; Burns KE
Br J Clin Pharmacol; 2019 Sep; 85(9):1925-1934. PubMed ID: 31218720
[TBL] [Abstract][Full Text] [Related]
5. Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide.
Ekhart C; Doodeman VD; Rodenhuis S; Smits PH; Beijnen JH; Huitema AD
Pharmacogenet Genomics; 2008 Jun; 18(6):515-23. PubMed ID: 18496131
[TBL] [Abstract][Full Text] [Related]
6. Cyclophosphamide bioactivation pharmacogenetics in breast cancer patients.
Helsby N; Yong M; Burns K; Findlay M; Porter D
Cancer Chemother Pharmacol; 2021 Sep; 88(3):533-542. PubMed ID: 34114066
[TBL] [Abstract][Full Text] [Related]
7. Cytochrome P450 Genetic Variations Can Predict mRNA Expression, Cyclophosphamide 4-Hydroxylation, and Treatment Outcomes in Chinese Patients With Non-Hodgkin's Lymphoma.
Shu W; Chen L; Hu X; Zhang M; Chen W; Ma L; Liu X; Huang J; Pang T; Li J; Zhang Y
J Clin Pharmacol; 2017 Jul; 57(7):886-898. PubMed ID: 28181240
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetics of cyclophosphamide in patients with hematological malignancies.
Xie H; Griskevicius L; Ståhle L; Hassan Z; Yasar U; Rane A; Broberg U; Kimby E; Hassan M
Eur J Pharm Sci; 2006 Jan; 27(1):54-61. PubMed ID: 16183265
[TBL] [Abstract][Full Text] [Related]
9. Cytochrome P450 polymorphism as a predictor of ovarian toxicity to pulse cyclophosphamide in systemic lupus erythematosus.
Singh G; Saxena N; Aggarwal A; Misra R
J Rheumatol; 2007 Apr; 34(4):731-3. PubMed ID: 17407229
[TBL] [Abstract][Full Text] [Related]
10. Association between CYP2C19 and CYP2B6 phenotypes and the pharmacokinetics and safety of diazepam.
Zubiaur P; Figueiredo-Tor L; Villapalos-García G; Soria-Chacartegui P; Navares-Gómez M; Novalbos J; Matas M; Calleja S; Mejía-Abril G; Román M; Ochoa D; Abad-Santos F
Biomed Pharmacother; 2022 Nov; 155():113747. PubMed ID: 36162369
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetic roles of CYP2C19 and CYP2B6 in the metabolism of R- and S-mephobarbital in humans.
Kobayashi K; Morita J; Chiba K; Wanibuchi A; Kimura M; Irie S; Urae A; Ishizaki T
Pharmacogenetics; 2004 Aug; 14(8):549-56. PubMed ID: 15284537
[TBL] [Abstract][Full Text] [Related]
12. Influence of CYP2B6 and CYP2C19 polymorphisms on sertraline metabolism in major depression patients.
Yuce-Artun N; Baskak B; Ozel-Kizil ET; Ozdemir H; Uckun Z; Devrimci-Ozguven H; Suzen HS
Int J Clin Pharm; 2016 Apr; 38(2):388-94. PubMed ID: 26830411
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetics of cyclophosphamide and CYP2C19 polymorphism in Thai systemic lupus erythematosus.
Ngamjanyaporn P; Thakkinstian A; Verasertniyom O; Chatchaipun P; Vanichapuntu M; Nantiruj K; Totemchokchyakarn K; Attia J; Janwityanujit S
Rheumatol Int; 2011 Sep; 31(9):1215-8. PubMed ID: 20358205
[TBL] [Abstract][Full Text] [Related]
14. Glutathione S Transferases Polymorphisms Are Independent Prognostic Factors in Lupus Nephritis Treated with Cyclophosphamide.
Audemard-Verger A; Martin Silva N; Verstuyft C; Costedoat-Chalumeau N; Hummel A; Le Guern V; Sacré K; Meyer O; Daugas E; Goujard C; Sultan A; Lobbedez T; Galicier L; Pourrat J; Le Hello C; Godin M; Morello R; Lambert M; Hachulla E; Vanhille P; Queffeulou G; Potier J; Dion JJ; Bataille P; Chauveau D; Moulis G; Farge-Bancel D; Duhaut P; Saint-Marcoux B; Deroux A; Manuzak J; Francès C; Aumaitre O; Bezanahary H; Becquemont L; Bienvenu B
PLoS One; 2016; 11(3):e0151696. PubMed ID: 27002825
[TBL] [Abstract][Full Text] [Related]
15. Association of CYP2B6, CYP3A5, and CYP2C19 genetic polymorphisms with sibutramine pharmacokinetics in healthy Korean subjects.
Kim KA; Song WK; Park JY
Clin Pharmacol Ther; 2009 Nov; 86(5):511-8. PubMed ID: 19693007
[TBL] [Abstract][Full Text] [Related]
16. Epistatic interactions among CYP2C19*2, CYP3A4 and GSTP1 on the cyclophosphamide therapy in lupus nephritis patients.
Kumaraswami K; Katkam SK; Aggarwal A; Sharma A; Manthri R; Kutala VK; Rajasekhar L
Pharmacogenomics; 2017 Oct; 18(15):1401-1411. PubMed ID: 28976264
[TBL] [Abstract][Full Text] [Related]
17. Effect of Polymorphisms on the Pharmacokinetics, Pharmacodynamics and Safety of Sertraline in Healthy Volunteers.
Saiz-Rodríguez M; Belmonte C; Román M; Ochoa D; Koller D; Talegón M; Ovejero-Benito MC; López-Rodríguez R; Cabaleiro T; Abad-Santos F
Basic Clin Pharmacol Toxicol; 2018 May; 122(5):501-511. PubMed ID: 29136336
[TBL] [Abstract][Full Text] [Related]
18. Cyclophosphamide and 4-hydroxycyclophosphamide pharmacokinetics in patients with glomerulonephritis secondary to lupus and small vessel vasculitis.
Joy MS; La M; Wang J; Bridges AS; Hu Y; Hogan SL; Frye RF; Blaisdell J; Goldstein JA; Dooley MA; Brouwer KL; Falk RJ
Br J Clin Pharmacol; 2012 Sep; 74(3):445-55. PubMed ID: 22380717
[TBL] [Abstract][Full Text] [Related]
19. The combined impact of CYP2C19 and CYP2B6 pharmacogenetics on cyclophosphamide bioactivation.
Helsby NA; Hui CY; Goldthorpe MA; Coller JK; Soh MC; Gow PJ; De Zoysa JZ; Tingle MD
Br J Clin Pharmacol; 2010 Dec; 70(6):844-53. PubMed ID: 21175440
[TBL] [Abstract][Full Text] [Related]
20. Genetic polymorphisms effect on cyclophosphamide's tolerability and clinical efficacy in Egyptian patients with lupus nephritis.
Abuelsoud NN; El Khateeb EM
Pharmacogenet Genomics; 2023 Oct; 33(8):172-180. PubMed ID: 37611146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
